Target intelligence / Profile preview

Off-target mRNAs with partial complementarity to JMJD3 siRNA guide strand

Molecular classification
Messenger RNA, Nucleic acid
01

Overview

Off-target mRNAs with partial complementarity to the JMJD3 siRNA guide strand represent a class of unintended molecular interactions occurring during RNA interference (RNAi) experiments or therapies. JMJD3, also known as KDM6B, is a histone H3K27 demethylase that plays a critical role in regulating gene expression during inflammation, development, and oncogenesis (Agger et al., 2007, Nature). When siRNAs are designed to silence JMJD3, the guide strand may bind to other mRNA transcripts that share sequence homology, particularly in the 3' untranslated region (UTR) matching the siRNA's seed sequence (Jackson et al., 2003, Nature Biotechnology). This binding leads to the degradation or translational repression of these non-target mRNAs, potentially causing phenotypic changes unrelated to JMJD3 inhibition. These off-target effects are a major hurdle in drug development, as they can lead to toxicity or false-positive results in functional genomics screens (Birmingham et al., 2006, Nature Methods). To minimize these risks, researchers employ chemical modifications, such as 2'-O-methyl groups, or use multiple siRNA sequences to validate findings (Fedorov et al., 2006, RNA). Understanding and predicting these off-target interactions is essential for the clinical translation of siRNA-based drugs targeting JMJD3.

Other names
siRNA off-target effectsSeed-sequence mediated off-targetsUnintended mRNA silencingKDM6B siRNA off-targetsRNAi off-targets
02

Mechanism of action

Sequence-specific mRNA degradation or translational repression via the RNA-induced silencing complex (RISC) triggered by partial complementarity, particularly within the seed region (nucleotides 2-8), to the 3' untranslated regions of unintended transcripts (Jackson et al., 2003, Nature Biotechnology).

03

Biological functions

Gene expression regulationRNA interferencePost-transcriptional silencing
04

Disease associations

ToxicitySide effectsOff-target toxicity
05

Safety considerations

Off-target toxicityFalse positive experimental resultsUnintended phenotypic changesCytotoxicitySaturation of the RNAi machinery
06

Interacting drugs

JMJD3 siRNA

1 more in the full profile.

07

Biomarkers

Global gene expression profilingRNA-seqMicroarray analysisReporter gene assays

Beyond the preview

Go deeper on Off-target mRNAs with partial complementarity to JMJD3 siRNA guide strand.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Off-target mRNAs with partial complementarity to JMJD3 siRNA guide strand.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call